B-Cell chronic lymphocytic leukemia

From Citizendium, the Citizens' Compendium
Jump to: navigation, search
This article is a stub and thus not approved.
Main Article
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
This editable Main Article is under development and not meant to be cited; by editing it you can help to improve it towards a future approved, citable version. These unapproved articles are subject to a disclaimer.

In medicine, B-Cell chronic lymphocytic leukemia, also called chronic lymphocytic leukemia (CLL), is a "chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominantly with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominantly with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease."[1][2][3]


5-Year Relative Survival Rates By Year Dx By Leukemia type All Ages, All Races, Both Sexes 1975-2000.

Staging information

B-Cell chronic lymphocytic leukemia staging information from the National Cancer Institute's Physician Data Query


B-Cell chronic lymphocytic leukemia treatment information from the National Cancer Institute's Physician Data Query

As a primary antineoplastic agent, fludarabine may be more effective than chlorambucil.[4]

Treatment options for Stage I, II, III, and IV CLL[5]
Regimen Effectiveness Adverse effects
• Fludarabine
• Cyclophosphamide
• Rituximab
Complete remission in 25% to 72% • Neutropenia
• 10% rate of infection during first year
• Rituximab induced fever (37%), chills (50%), hypotension (13%), nausea and vomiting


  1. Anonymous (2015), B-Cell chronic lymphocytic leukemia (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE (September 2006). "Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia". Ann. Intern. Med. 145 (6): 435–47. PMID 16983131[e]
  3. Chiorazzi N, Rai KR, Ferrarini M (February 2005). "Chronic lymphocytic leukemia". N. Engl. J. Med. 352 (8): 804–15. DOI:10.1056/NEJMra041720. PMID 15728813. Research Blogging.
  4. Rai KR, Peterson BL, Appelbaum FR, et al (December 2000). "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia". N. Engl. J. Med. 343 (24): 1750–7. PMID 11114313[e]
  5. Anonymous. Chronic Lymphocytic Leukemia Treatment -. National Cancer Institute. Retrieved on 2009-03-31.
  6. Wierda W, O'Brien S, Wen S, et al (June 2005). "Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia". J. Clin. Oncol. 23 (18): 4070–8. DOI:10.1200/JCO.2005.12.516. PMID 15767647. Retrieved on 2009-03-31. Research Blogging.
  7. Tam CS, O'Brien S, Wierda W, et al (August 2008). "Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia". Blood 112 (4): 975–80. DOI:10.1182/blood-2008-02-140582. PMID 18411418. Retrieved on 2009-03-31. Research Blogging.